Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection

作     者：Lun-Gen Lu 

作者机构：Department of Gastroenterology Shanghai First People's Hospital Shanghai Jiaotong University School of Medicine Shanghai China 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2014年第2卷第3期

页      面：197-201页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the National Key Technologies Research and Development Program of China during the 11th/12th Five-year Plan Period (no.2008ZX1002-006 2012ZX10002007-001-040 and 2013ZX10002004-002-003) 

主　　题：Hepatitis B virus Chronic HBV infection Liver cirrhosis Antiviral therapy 

摘      要：Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific *** one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each *** left untreated,6-20% of chronic hepatitis B (CrHB) patients will develop cirrhosis over five *** cumulative incidence of HBV-related cirrhosis,disease progression,and prognosis are closely associated with serum HBV DNA *** therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and *** approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related ***,we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.